melatonin has been researched along with Glaucoma in 33 studies
Glaucoma: An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study the levels of melatonin in the aqueous humour of normotensive and hypertensive intraocular pressure (IOP) patients and to compare them to an animal model of glaucoma." | 7.85 | Elevated intraocular pressure increases melatonin levels in the aqueous humour. ( Alkozi, H; Carracedo, G; de Lara, MJ; Fonseca, B; Martinez-Aguila, A; Pintor, J; Sánchez-Naves, J, 2017) |
| "Melatonin is a pineal hormone that has a capacity to lower intraocular pressure; it exhibits neuroprotective and antioxidant properties that make it possible to use melatonin in the therapy of glaucoma." | 7.85 | [Novel agonists of melatonin receptors as promising hypotensive and neuroprotective agents for therapy of glaucoma]. ( Beznos, OV; Chesnokova, NB; Grigoryev, AV; Lozinskaya, NA; Volkova, MS; Zaryanova, EV; Zefirov, NA, 2017) |
| " Using both control C57BL/6J and glaucomatous DBA/2J mice as well as TonoLab tonometry, this study evaluated the effect of melatonin and 5-methoxycarbonylamino-N-acetyltryptamine (5-MCA-NAT) when glaucomatous pathology was fully established and compared pharmacological behavior in treated mice versus control mice." | 7.83 | Effect of Melatonin and 5-Methoxycarbonylamino-N-Acetyltryptamine on the Intraocular Pressure of Normal and Glaucomatous Mice. ( Fonseca, B; Martínez-Águila, A; Pérez de Lara, MJ; Pintor, J, 2016) |
| "Melatonin is currently considered a promising drug for glaucoma treatment because of its ocular hypotensive and neuroprotective effects." | 7.79 | Melatonin and its analog 5-methoxycarbonylamino-N-acetyltryptamine potentiate adrenergic receptor-mediated ocular hypotensive effects in rabbits: significance for combination therapy in glaucoma. ( Crooke, A; Huete-Toral, F; Martín-Gil, A; Martínez-Águila, A; Pintor, J, 2013) |
| "We explored the melatonin influence on the level of amino acid neurotransmitters of the retina in glaucoma neuropathy in rats." | 7.79 | [Protective action of melatonin in experimental glaucoma in rats]. ( Mykheĭtseva, IM, 2013) |
| "Melatonin, the MT(2) melatonin receptor agonist IIK7 [N-butanoyl-2-(2-methoxy-6H-isoindolo[2,1-a]indol-11-yl)ethanamine], and the putative MT(3) melatonin receptor agonist 5-MCA-NAT [5-methoxycarbonylamino-N-acetyltryptamine] have previously been shown to reduce intraocular pressure (IOP) in ocular normotensive rabbits." | 7.77 | Design of novel melatonin analogs for the reduction of intraocular pressure in normotensive rabbits. ( Alarma-Estrany, P; Guzman-Aranguez, A; Huete, F; Pelaez, T; Peral, A; Pintor, J; Plourde, R; Yerxa, B, 2011) |
| "As previous studies have suggested that melatonin and serotonin may be involved in the regulation of intraocular pressure, retinal concentrations of melatonin, 5-HT, and related indoleamines measured at day and at night were studied during the development of a glaucoma-like disorder with increased intraocular pressure in the al mutant quail." | 7.70 | Day and night dysfunction in intraretinal melatonin and related indoleamines metabolism, correlated with the development of glaucoma-like disorder in an avian model. ( Chanut, E; Dkhissi, O; Nguyen-Legros, J; Repérant, J; Trouvin, JH; Versaux-Botteri, C, 1998) |
| "The possible involvement of a melatonergic mechanism in the control of intraocular pressure (IOP) and the genesis of light-induced avian glaucoma (LIAG) was studied by measuring N-acetyltransferase (NAT) activity and melatonin levels in the iris, ciliary body and retina-choroid during the course of LIAG development, and in normal subjects by day and night." | 7.67 | N-acetyltransferase activity and melatonin level in the eyes of glaucomatous chickens. ( Aimoto, T; Chiou, GC; Lauber, JK; Rohde, BH, 1985) |
| "Melatonin is a hormone secreted into the blood mainly from the pineal gland allowing the entrainment of the circadian rhythms of several biological functions." | 6.48 | Update in glaucoma medicinal chemistry: emerging evidence for the importance of melatonin analogues. ( Colligris, B; Crooke, A; Pintor, J, 2012) |
| "Glaucoma is a frequent ophthalmologic condition leading to chronic progressive optic neuropathy, which can result in visual impairment and blindness." | 6.47 | The role of melatonin in glaucoma: implications concerning pathophysiological relevance and therapeutic potential. ( Agorastos, A; Huber, CG, 2011) |
| "Acute ocular hypertension (AOH) is the most important characteristic of acute glaucoma, which can lead to retinal ganglion cell (RGC) death and permanent vision loss." | 5.72 | Anti-PANoptosis is involved in neuroprotective effects of melatonin in acute ocular hypertension model. ( Bai, X; Cui, K; Fan, M; Feng, Y; Hu, C; Huang, J; Huang, W; Liang, X; Liao, J; Lu, P; Shi, Y; Tang, X; Xu, F; Xu, Y; Ye, D, 2022) |
| "Glaucoma is a blindness-causing disease that involves selective damage to retinal ganglion cells (RGCs) and their axons." | 5.62 | Melatonin Prevents Non-image-Forming Visual System Alterations Induced by Experimental Glaucoma in Rats. ( Aranda, ML; Calanni, JS; Devouassoux, J; Dieguez, HH; Dorfman, D; González Fleitas, MF; Iaquinandi, A; Rosenstein, RE; Sande, PH, 2021) |
| "Concomitantly, gliosis-related inflammation and the Bax-associated apoptosis were partially prevented, thus leading to RGC survival and recovered retinal dysfunction." | 5.56 | A Topical Formulation of Melatoninergic Compounds Exerts Strong Hypotensive and Neuroprotective Effects in a Rat Model of Hypertensive Glaucoma. ( Amato, R; Bagnoli, P; Cammalleri, M; Corsaro, R; Dal Monte, M; Pezzino, S; Rusciano, D, 2020) |
| "Glaucoma is a leading cause of blindness." | 5.36 | Melatonin: a novel neuroprotectant for the treatment of glaucoma. ( Belforte, NA; Chianelli, MS; de Zavalía, N; Keller Sarmiento, MI; Moreno, MC; Rosenstein, RE; Sande, PH, 2010) |
| "We aimed to compare the neuroprotective effects of brimonidine tartrate (BRT) and melatonin (MEL) on retinal ganglion cells (RGCs) in a rat glaucoma model." | 3.88 | Comparison of the neuroprotective effects of brimonidine tartrate and melatonin on retinal ganglion cells. ( Ciftci, F; Eyuboglu, S; Gumusel, A; Guzel, E; Marangoz, D; Seckin, I; Yalvac, I; Yilmaz, B, 2018) |
| "To study the levels of melatonin in the aqueous humour of normotensive and hypertensive intraocular pressure (IOP) patients and to compare them to an animal model of glaucoma." | 3.85 | Elevated intraocular pressure increases melatonin levels in the aqueous humour. ( Alkozi, H; Carracedo, G; de Lara, MJ; Fonseca, B; Martinez-Aguila, A; Pintor, J; Sánchez-Naves, J, 2017) |
| "Melatonin is a pineal hormone that has a capacity to lower intraocular pressure; it exhibits neuroprotective and antioxidant properties that make it possible to use melatonin in the therapy of glaucoma." | 3.85 | [Novel agonists of melatonin receptors as promising hypotensive and neuroprotective agents for therapy of glaucoma]. ( Beznos, OV; Chesnokova, NB; Grigoryev, AV; Lozinskaya, NA; Volkova, MS; Zaryanova, EV; Zefirov, NA, 2017) |
| " Using both control C57BL/6J and glaucomatous DBA/2J mice as well as TonoLab tonometry, this study evaluated the effect of melatonin and 5-methoxycarbonylamino-N-acetyltryptamine (5-MCA-NAT) when glaucomatous pathology was fully established and compared pharmacological behavior in treated mice versus control mice." | 3.83 | Effect of Melatonin and 5-Methoxycarbonylamino-N-Acetyltryptamine on the Intraocular Pressure of Normal and Glaucomatous Mice. ( Fonseca, B; Martínez-Águila, A; Pérez de Lara, MJ; Pintor, J, 2016) |
| "Melatonin is currently considered a promising drug for glaucoma treatment because of its ocular hypotensive and neuroprotective effects." | 3.79 | Melatonin and its analog 5-methoxycarbonylamino-N-acetyltryptamine potentiate adrenergic receptor-mediated ocular hypotensive effects in rabbits: significance for combination therapy in glaucoma. ( Crooke, A; Huete-Toral, F; Martín-Gil, A; Martínez-Águila, A; Pintor, J, 2013) |
| "We explored the melatonin influence on the level of amino acid neurotransmitters of the retina in glaucoma neuropathy in rats." | 3.79 | [Protective action of melatonin in experimental glaucoma in rats]. ( Mykheĭtseva, IM, 2013) |
| "Melatonin, the MT(2) melatonin receptor agonist IIK7 [N-butanoyl-2-(2-methoxy-6H-isoindolo[2,1-a]indol-11-yl)ethanamine], and the putative MT(3) melatonin receptor agonist 5-MCA-NAT [5-methoxycarbonylamino-N-acetyltryptamine] have previously been shown to reduce intraocular pressure (IOP) in ocular normotensive rabbits." | 3.77 | Design of novel melatonin analogs for the reduction of intraocular pressure in normotensive rabbits. ( Alarma-Estrany, P; Guzman-Aranguez, A; Huete, F; Pelaez, T; Peral, A; Pintor, J; Plourde, R; Yerxa, B, 2011) |
| "As previous studies have suggested that melatonin and serotonin may be involved in the regulation of intraocular pressure, retinal concentrations of melatonin, 5-HT, and related indoleamines measured at day and at night were studied during the development of a glaucoma-like disorder with increased intraocular pressure in the al mutant quail." | 3.70 | Day and night dysfunction in intraretinal melatonin and related indoleamines metabolism, correlated with the development of glaucoma-like disorder in an avian model. ( Chanut, E; Dkhissi, O; Nguyen-Legros, J; Repérant, J; Trouvin, JH; Versaux-Botteri, C, 1998) |
| " Here we describe three experiments which investigated: (i) the effects of sleep in five groups of subjects: glaucoma, suspect glaucoma, young high-normal IOP, old high-normal IOP groups and an elderly control group, (ii) the effect of exposure to bright light (2500 lux) during sleep on associated IOP changes, and (iii) the relationship between changes in IOP and plasma melatonin during sleep." | 3.68 | Investigation of parameters influencing intraocular pressure increases during sleep. ( Brown, B; Eyeson-Annan, M; Fletcher, T; Swann, PG; Wildsoet, C, 1993) |
| "Melatonin is a hormone secreted into the blood mainly from the pineal gland allowing the entrainment of the circadian rhythms of several biological functions." | 2.48 | Update in glaucoma medicinal chemistry: emerging evidence for the importance of melatonin analogues. ( Colligris, B; Crooke, A; Pintor, J, 2012) |
| "Glaucoma is a neurodegenerative pathology that affects the optic nerve producing blindness." | 2.45 | New treatments for ocular hypertension. ( Alarma-Estrany, P; Mediero, A; Pintor, J, 2009) |
| "Acute ocular hypertension (AOH) is the most important characteristic of acute glaucoma, which can lead to retinal ganglion cell (RGC) death and permanent vision loss." | 1.72 | Anti-PANoptosis is involved in neuroprotective effects of melatonin in acute ocular hypertension model. ( Bai, X; Cui, K; Fan, M; Feng, Y; Hu, C; Huang, J; Huang, W; Liang, X; Liao, J; Lu, P; Shi, Y; Tang, X; Xu, F; Xu, Y; Ye, D, 2022) |
| "Melatonin (MT) is an indole neuroendocrine hormone mainly secreted by the pineal gland." | 1.72 | The neuroprotective effect of melatonin in glutamate excitotoxicity of R28 cells and mouse retinal ganglion cells. ( An, Y; Ding, L; Li, H; Song, S; Wang, C; Xia, X; Xia, Z; Zhou, X, 2022) |
| "Concomitantly, gliosis-related inflammation and the Bax-associated apoptosis were partially prevented, thus leading to RGC survival and recovered retinal dysfunction." | 1.56 | A Topical Formulation of Melatoninergic Compounds Exerts Strong Hypotensive and Neuroprotective Effects in a Rat Model of Hypertensive Glaucoma. ( Amato, R; Bagnoli, P; Cammalleri, M; Corsaro, R; Dal Monte, M; Pezzino, S; Rusciano, D, 2020) |
| "Glaucoma is a multifactorial neurodegenerative disorder and one of the leading causes of irreversible blindness globally and for which intraocular pressure is the only modifiable risk factor." | 1.51 | Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma. ( Arranz-Romera, A; Bravo-Osuna, I; Cordeiro, MF; Davis, BM; Esteban-Pérez, S; Guo, L; Herrero-Vanrell, R; Molina-Martínez, IT; Ravindran, N; Shamsher, E, 2019) |
| "Glaucoma is a leading cause of blindness worldwide, characterized by retinal ganglion cell degeneration and damage to the optic nerve." | 1.37 | Effect of experimental glaucoma on the non-image forming visual system. ( Belforte, N; de Zavalía, N; Fernandez, DC; Golombek, DA; Lanzani, MF; Plano, SA; Rosenstein, RE; Salido, E; Sarmiento, MI, 2011) |
| "Glaucoma is a leading cause of blindness." | 1.36 | Melatonin: a novel neuroprotectant for the treatment of glaucoma. ( Belforte, NA; Chianelli, MS; de Zavalía, N; Keller Sarmiento, MI; Moreno, MC; Rosenstein, RE; Sande, PH, 2010) |
| "Glaucoma is an optic neuropathy in which retinal ganglion cells die probably through an apoptotic process." | 1.32 | Retinal oxidative stress induced by high intraocular pressure. ( Campanelli, J; Keller Sarmiento, MI; Moreno, MC; Rosenstein, RE; Sande, P; Sánez, DA, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (9.09) | 18.7374 |
| 1990's | 2 (6.06) | 18.2507 |
| 2000's | 5 (15.15) | 29.6817 |
| 2010's | 15 (45.45) | 24.3611 |
| 2020's | 8 (24.24) | 2.80 |
| Authors | Studies |
|---|---|
| Ye, D | 1 |
| Xu, Y | 1 |
| Shi, Y | 1 |
| Fan, M | 1 |
| Lu, P | 1 |
| Bai, X | 1 |
| Feng, Y | 1 |
| Hu, C | 1 |
| Cui, K | 1 |
| Tang, X | 1 |
| Liao, J | 1 |
| Huang, W | 1 |
| Xu, F | 1 |
| Liang, X | 1 |
| Huang, J | 1 |
| Wang, C | 1 |
| An, Y | 1 |
| Xia, Z | 1 |
| Zhou, X | 1 |
| Li, H | 1 |
| Song, S | 1 |
| Ding, L | 1 |
| Xia, X | 1 |
| Alkozi, HA | 1 |
| Navarro, G | 1 |
| Franco, R | 1 |
| Pintor, J | 7 |
| Scuderi, L | 1 |
| Davinelli, S | 1 |
| Iodice, CM | 1 |
| Bartollino, S | 1 |
| Scapagnini, G | 1 |
| Costagliola, C | 1 |
| Scuderi, G | 1 |
| Yoshikawa, T | 1 |
| Obayashi, K | 1 |
| Miyata, K | 1 |
| Saeki, K | 1 |
| Ogata, N | 1 |
| Adornetto, A | 1 |
| Rombolà, L | 1 |
| Morrone, LA | 1 |
| Nucci, C | 1 |
| Corasaniti, MT | 1 |
| Bagetta, G | 1 |
| Russo, R | 1 |
| Dal Monte, M | 1 |
| Cammalleri, M | 1 |
| Amato, R | 1 |
| Pezzino, S | 1 |
| Corsaro, R | 1 |
| Bagnoli, P | 1 |
| Rusciano, D | 1 |
| Martínez-Águila, A | 4 |
| Martín-Gil, A | 2 |
| Carpena-Torres, C | 1 |
| Pastrana, C | 1 |
| Carracedo, G | 2 |
| González Fleitas, MF | 1 |
| Devouassoux, J | 1 |
| Aranda, ML | 1 |
| Dieguez, HH | 1 |
| Calanni, JS | 1 |
| Iaquinandi, A | 1 |
| Sande, PH | 2 |
| Dorfman, D | 1 |
| Rosenstein, RE | 7 |
| Marangoz, D | 1 |
| Guzel, E | 1 |
| Eyuboglu, S | 1 |
| Gumusel, A | 1 |
| Seckin, I | 1 |
| Ciftci, F | 1 |
| Yilmaz, B | 1 |
| Yalvac, I | 1 |
| Arranz-Romera, A | 1 |
| Davis, BM | 1 |
| Bravo-Osuna, I | 1 |
| Esteban-Pérez, S | 1 |
| Molina-Martínez, IT | 1 |
| Shamsher, E | 1 |
| Ravindran, N | 1 |
| Guo, L | 1 |
| Cordeiro, MF | 1 |
| Herrero-Vanrell, R | 1 |
| Crooke, A | 2 |
| Huete-Toral, F | 1 |
| Mykheĭtseva, IM | 1 |
| Münch, M | 1 |
| Léon, L | 1 |
| Collomb, S | 1 |
| Kawasaki, A | 1 |
| Fonseca, B | 2 |
| Pérez de Lara, MJ | 1 |
| Alkozi, H | 1 |
| Sánchez-Naves, J | 1 |
| de Lara, MJ | 1 |
| Chesnokova, NB | 1 |
| Beznos, OV | 1 |
| Lozinskaya, NA | 1 |
| Volkova, MS | 1 |
| Zaryanova, EV | 1 |
| Zefirov, NA | 1 |
| Grigoryev, AV | 1 |
| Mediero, A | 1 |
| Alarma-Estrany, P | 2 |
| Belforte, NA | 1 |
| Moreno, MC | 3 |
| de Zavalía, N | 3 |
| Chianelli, MS | 1 |
| Keller Sarmiento, MI | 3 |
| Pandi-Perumal, SR | 2 |
| Srinivasan, V | 2 |
| Spence, DW | 1 |
| Brown, GM | 1 |
| Cardinali, DP | 2 |
| Agorastos, A | 1 |
| Huber, CG | 1 |
| Guzman-Aranguez, A | 1 |
| Huete, F | 1 |
| Peral, A | 1 |
| Plourde, R | 1 |
| Pelaez, T | 1 |
| Yerxa, B | 1 |
| Plano, SA | 1 |
| Fernandez, DC | 1 |
| Lanzani, MF | 1 |
| Salido, E | 1 |
| Belforte, N | 1 |
| Sarmiento, MI | 1 |
| Golombek, DA | 1 |
| Colligris, B | 1 |
| Campanelli, J | 1 |
| Sande, P | 2 |
| Sánez, DA | 1 |
| Marcos, HA | 1 |
| Siu, AW | 1 |
| Maldonado, M | 1 |
| Sanchez-Hidalgo, M | 1 |
| Tan, DX | 1 |
| Reiter, RJ | 1 |
| Lundmark, PO | 1 |
| Rudin, DO | 1 |
| Wildsoet, C | 1 |
| Eyeson-Annan, M | 1 |
| Brown, B | 1 |
| Swann, PG | 1 |
| Fletcher, T | 1 |
| Dkhissi, O | 1 |
| Chanut, E | 1 |
| Versaux-Botteri, C | 1 |
| Trouvin, JH | 1 |
| Repérant, J | 1 |
| Nguyen-Legros, J | 1 |
| Lauber, JK | 2 |
| Oishi, T | 1 |
| Vriend, J | 1 |
| Aimoto, T | 1 |
| Rohde, BH | 1 |
| Chiou, GC | 1 |
10 reviews available for melatonin and Glaucoma
| Article | Year |
|---|---|
Melatonin and the control of intraocular pressure.
Topics: Animals; Aqueous Humor; Glaucoma; Humans; Intraocular Pressure; Melatonin | 2020 |
Melatonin: Implications for Ocular Disease and Therapeutic Potential.
Topics: Aging; Eye; Free Radicals; Glaucoma; Humans; Melatonin; Uveitis | 2019 |
Natural Products: Evidence for Neuroprotection to Be Exploited in Glaucoma.
Topics: Amides; Biological Products; Colforsin; Curcumin; Cytidine Diphosphate Choline; Dietary Supplements; | 2020 |
Influence of Circadian Rhythm in the Eye: Significance of Melatonin in Glaucoma.
Topics: Animals; Circadian Rhythm; Dry Eye Syndromes; Glaucoma; Humans; Intraocular Pressure; Melatonin; Myo | 2021 |
New treatments for ocular hypertension.
Topics: Adrenergic Agents; Animals; Eye; Glaucoma; Humans; Melatonin; Neuropharmacology; Nucleotides; Ocular | 2009 |
Melatonin as a therapeutic tool in ophthalmology: implications for glaucoma and uveitis.
Topics: Animals; Glaucoma; Humans; Melatonin; Neuroprotective Agents; Ophthalmology; Receptors, Melatonin; U | 2010 |
The role of melatonin in glaucoma: implications concerning pathophysiological relevance and therapeutic potential.
Topics: Animals; Circadian Rhythm; Glaucoma; Humans; Melatonin; Retinal Ganglion Cells | 2011 |
Update in glaucoma medicinal chemistry: emerging evidence for the importance of melatonin analogues.
Topics: Animals; Chemistry, Pharmaceutical; Glaucoma; Humans; Intraocular Pressure; Melatonin; Molecular Str | 2012 |
Protective effects of melatonin in experimental free radical-related ocular diseases.
Topics: Antioxidants; Cataract; Eye Diseases; Glaucoma; Humans; Keratitis; Melatonin; Ocular Physiological P | 2006 |
Melatonin in the eye: implications for glaucoma.
Topics: Animals; Antioxidants; Eye; Glaucoma; Humans; Intraocular Pressure; Melatonin; Oxidative Stress; Rec | 2007 |
1 trial available for melatonin and Glaucoma
| Article | Year |
|---|---|
Decreased melatonin secretion in patients with glaucoma: Quantitative association with glaucoma severity in the LIGHT study.
Topics: Aged; Aged, 80 and over; Circadian Rhythm; Female; Glaucoma; Humans; Male; Melatonin; Middle Aged; S | 2020 |
22 other studies available for melatonin and Glaucoma
| Article | Year |
|---|---|
Anti-PANoptosis is involved in neuroprotective effects of melatonin in acute ocular hypertension model.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspase 8; DNA Nucleotidylexotransferase; | 2022 |
The neuroprotective effect of melatonin in glutamate excitotoxicity of R28 cells and mouse retinal ganglion cells.
Topics: Animals; Glaucoma; Glutamic Acid; Melatonin; Mice; N-Methylaspartate; Neuroprotective Agents; Reacti | 2022 |
A Topical Formulation of Melatoninergic Compounds Exerts Strong Hypotensive and Neuroprotective Effects in a Rat Model of Hypertensive Glaucoma.
Topics: Acetamides; Animals; Antihypertensive Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Dise | 2020 |
Melatonin Prevents Non-image-Forming Visual System Alterations Induced by Experimental Glaucoma in Rats.
Topics: Animals; Antioxidants; Glaucoma; Light; Male; Melatonin; Rats; Rats, Wistar; Retinal Ganglion Cells; | 2021 |
Comparison of the neuroprotective effects of brimonidine tartrate and melatonin on retinal ganglion cells.
Topics: Animals; Antioxidants; Apoptosis; Brimonidine Tartrate; Disease Models, Animal; Glaucoma; Intraocula | 2018 |
Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma.
Topics: Animals; Dexamethasone; Disease Models, Animal; Drug Carriers; Drug Compounding; Drug Liberation; Dr | 2019 |
Melatonin and its analog 5-methoxycarbonylamino-N-acetyltryptamine potentiate adrenergic receptor-mediated ocular hypotensive effects in rabbits: significance for combination therapy in glaucoma.
Topics: Adrenergic Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Antagonists; Animals; Cel | 2013 |
[Protective action of melatonin in experimental glaucoma in rats].
Topics: Animals; Antioxidants; Aspartic Acid; Chromatography, Ion Exchange; Epinephrine; gamma-Aminobutyric | 2013 |
Comparison of acute non-visual bright light responses in patients with optic nerve disease, glaucoma and healthy controls.
Topics: Adult; Case-Control Studies; Female; Glaucoma; Humans; Light; Male; Melatonin; Middle Aged; Optic Ne | 2015 |
Effect of Melatonin and 5-Methoxycarbonylamino-N-Acetyltryptamine on the Intraocular Pressure of Normal and Glaucomatous Mice.
Topics: Animals; Dose-Response Relationship, Drug; Glaucoma; Intraocular Pressure; Melatonin; Mice; Mice, In | 2016 |
Elevated intraocular pressure increases melatonin levels in the aqueous humour.
Topics: Adult; Aged; Aged, 80 and over; Animals; Aqueous Humor; Biomarkers; Chromatography, High Pressure Li | 2017 |
[Novel agonists of melatonin receptors as promising hypotensive and neuroprotective agents for therapy of glaucoma].
Topics: Animals; Antioxidants; Drug Design; Gene Expression; Glaucoma; Indoles; Intraocular Pressure; Ligand | 2017 |
Melatonin: a novel neuroprotectant for the treatment of glaucoma.
Topics: Animals; Arginine; gamma-Aminobutyric Acid; Glaucoma; Glutamate Decarboxylase; Glutamic Acid; Histoc | 2010 |
Design of novel melatonin analogs for the reduction of intraocular pressure in normotensive rabbits.
Topics: Animals; Dose-Response Relationship, Drug; Drug Design; Eye; Glaucoma; Intraocular Pressure; Isoindo | 2011 |
Effect of experimental glaucoma on the non-image forming visual system.
Topics: Animals; Anterior Eye Segment; Blotting, Western; Cell Count; Chondroitin Sulfates; Eye; Glaucoma; I | 2011 |
Retinal oxidative stress induced by high intraocular pressure.
Topics: Animals; Antioxidants; Free Radicals; Glaucoma; Glutathione; Hyaluronic Acid; Intraocular Pressure; | 2004 |
Effect of glaucoma on the retinal glutamate/glutamine cycle activity.
Topics: Animals; Glaucoma; Glutamate-Ammonia Ligase; Glutamic Acid; Glutaminase; Glutamine; Hyaluronic Acid; | 2005 |
Glaucoma, "auditory glaucoma", "articular glaucoma" and the third eye.
Topics: Arthritis; Basement Membrane; Cell Membrane Permeability; Glaucoma; Humans; Lipid Metabolism; Melato | 1980 |
Investigation of parameters influencing intraocular pressure increases during sleep.
Topics: Adult; Age Factors; Aged; Female; Glaucoma; Humans; Intraocular Pressure; Light; Male; Melatonin; Mi | 1993 |
Day and night dysfunction in intraretinal melatonin and related indoleamines metabolism, correlated with the development of glaucoma-like disorder in an avian model.
Topics: Acetylserotonin O-Methyltransferase; Aging; Amines; Animals; Circadian Rhythm; Coturnix; Glaucoma; H | 1998 |
Plasma melatonin rhythm lost in preglaucomatous chicks.
Topics: Animals; Chickens; Circadian Rhythm; Corticosterone; Glaucoma; Light; Melatonin; Thyroxine | 1986 |
N-acetyltransferase activity and melatonin level in the eyes of glaucomatous chickens.
Topics: Acetyltransferases; Animals; Arylamine N-Acetyltransferase; Chickens; Choline O-Acetyltransferase; E | 1985 |